New diagnostic and therapeutic tools
against multidrug resistant tumours

Scientific publications

Please, add the following sentence for any scientific publication related to the Pandora COST Innovators Grant:

This work was performed within the framework of COST Innovators Grant IG17104 PANDORA -”Pan-European Educational Platform on Multidrug Resistant Tumours and Personalised Cancer Treatment”.

After publication of a contribution related to the Pandora COST Innovators Grant, please send the citation as formatted in the first paper to stratagem.cost@gmail.com

  1. Rebelo R, Xavier CPR, Giovannetti E, Vasconcelos MH. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends in Molecular Medicine. 2023, 29, 6, 439-453, doi: 10.1016/j.molmed.2023.03.002
  2. Jurkovicova D, Neophytou CM, Gašparović AČ, Gonçalves AC. DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. International Journal of Molecular Sciences. 2022, 23(23), 14672. doi: 10.3390/ijms232314672
  3. Šimoničová K, Janotka Ľ, Kavcová H, Sulová Z, Breier A, Messingerova L. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resistance Updates. 2022, 100805. doi: 10.1016/j.drup.2022.100805
  4. Holasová K, Křížkovská B, Hoang L, Dobiasová S, Lipov J, Macek T, et al. Flavonolignans from silymarin modulate antibiotic resistance and virulence in Staphylococcus aureus. Biomedicine & Pharmacotherapy. 2022, 149, 112806. doi: 10.1016/j.biopha.2022.112806
  5. Anobile DP, Montenovo G, Pecoraro C, Franczak M, Ait Iddouch W, Peters GJ, Riganti C, Giovannetti E. Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma. Expert Rev Clin Pharmacol. 2022,  15 ,3 , 305-322. doi: 10.1080/17512433.2022.2074835
  6. Anobile DP, Niso M, Puerta A, Fraga Rodrigues SM, Abatematteo FS, Avan A, Abate C, Riganti C, Giovannetti E. New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4. Molecules. 2022 4, 27, 5, 1682. doi: 10.3390/molecules27051682
  7. Yalçin-Özkat G. Computational studies with flavonoids and terpenoids as BRPF1 inhibitors: in silico biological activity prediction, molecular docking, molecular dynamics simulations, MM/PBSA calculations. SAR and QSAR in Environmental Research. 2022, 33, 7, 533-550, doi: 10.1080/1062936X.2022.2096113
  8. Xavier CPR, Belisario DC, Rebelo R, Assaraf YG, Giovannetti E, Kopecka J, Vasconcelos MH. The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells. Drug Resist Updat. 2022, 62, 100833. doi: 10.1016/j.drup.2022.100833
  9. Van den bossche V., Zaryouh H, Vara-Messler M, Vignau J, Machiels JP, Wouters A, Schmitz S, Corbet C. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Drug Resistance Updates. 2022, 60, 100806, doi: 10.1016/j.drup.2022.100806
  10. Domínguez-Álvarez E, Rácz B, Marć MA, Nasim MJ, Szemerédi N, Viktorová J, Jacob C, Spengler G. Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents. Drug Resistance Updates. 2022, doi: 10.1016/j.drup.2022.100844
  11. Ntungwe EN, Stojanov SJ, Duarte NM, Candeias NR, Diaz-Lanza AM, Vagvolgyi M, Hunyadi A, Pesic M, Rijo P. C20-nor-Abietane and Three Abietane Diterpenoids from Plectranthus mutabilis Leaves as PGlycoprotein Modulators. ACS Medicinal Chemistry Letters. 2022, doi: 10.1021/acsmedchemlett.1c00711
  12. Coluccia A, Bufano M, La Regina G, Puxeddu M, Toto A, Paone A, Bouzidi A, Musto G, Badolati N, Orlando V, Biagioni S, Masci D, Cantatore C, Cirilli R, Cutruzzolà F, Gianni S, Stornaiuolo M, Silvestri R. Anticancer Activity of (S)-5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((pyridin-4-ylmethyl)amino)propan-2-yl)-1H-indole-2-carboxamide (RS4690), a New Dishevelled 1 Inhibitor. Cancers. 2022, 5, 14, 1358. doi: 10.3390/cancers14051358
  13. Alov P, Al Sharif M, Aluani D, Chegaev K, Dinic J, Rankov AD, Fernandes MX, Fusi F, García-Sosa AT, Juvonen RO, Kondeva-Burdina M, Padrón JM, Pajeva I, Pencheva T, Puerta A, Raunio H, Riganti C, Tsakovska I, Tzankova V, Yordanov Y, Saponara S.  A comprehensive evaluation of Sdox, a promising H2S-releasing doxorubicin for the treatment of chemoresistant tumors. Frontiers in Pharmacology. 2022 doi: 10.3389/fphar.2022.831791
  14. Durante M, Frosini M, Chiaino E, Fusi F, Gamberucci A, Gorelli B, Chegaev K, Riganti C, Saponara S. Sdox, a H2S releasing anthracycline, with a safer profile than doxorubicin toward vasculature. Vascul Pharmacol. 2022 143: 106969. doi: 10.1016/j.vph.2022.106969
  15. Cardoso DS, Szemerédi N, Spengler G, Mulhovo S, Dos Santos DJ, Ferreira MJU. Exploring the monoterpene indole alkaloid scaffold for reversing P-glycoprotein-mediated multidrug resistance in cancer. Pharmaceuticals. 2021, 14, 9, p.862. doi: 10.3390/ph14090862
  16. Cardoso DS, Kincses A, Nové M, Spengler G, Mulhovo S, Aires-de-Sousa J, Dos Santos DJ, Ferreira MJU. Alkylated monoterpene indole alkaloid derivatives as potent P-glycoprotein inhibitors in resistant cancer cells. European Journal of Medicinal Chemistry. 2021, 210, 112985. doi: 10.1016/j.ejmech.2020.112985
  17. Yalcin-Ozkat G. Molecular Modeling Strategies of Cancer Multidrug Resistance. Drug Resistance Updates. 2021, 59, 100789. doi: 10.1016/j.drup.2021.100789
  18. Szemeredi N, Dobiasova S, Salardon-Jimenez N, Kincses A, Nove M, Habibullah G, et al. Cyano- and Ketone-Containing Selenoesters as Multi-Target Compounds against Resistant Cancers. Cancers. 2021, 13, 4563. doi: 10.3390/cancers13184563
  19. Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers. 2021, 13, 4364. doi: 10.3390/cancers13174363
  20. Gonçalves AC, Richiardone E, Jorge J, Polónia B, Xavier CPR, Salaroglio IC, Riganti C, Vasconcelos MH, Corbet C, Sarmento-Ribeiro AB. Impact of cancer metabolism on therapy resistance – Clinical implications. Drug Resist Updat. 2021, 59, 100797. doi: 10.1016/j.drup.2021.100797
  21. Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, Riganti C. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat. 2021, 59, 100787. doi: 10.1016/j.drup.2021.100787
  22. Fallani E, Cevenini F, Lazzerini PE, Verdini A, Saponara S. Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. J Clin Pharmacol. 2021 doi: https://doi.org/10.1002/jcph.2006
  23. Stathopoulou M, Zoupanou N, Banti C, Douvalis A, Papachristodoulou C, Marousis K, Spyroulias G, Mavromoustakos T, Hadjikakou S. Organotin derivatives of cholic acid induce apoptosis into breast cancer cells and interfere with mitochondrion; Synthesis, characterization and biological evaluation. Steroids. 2021, 167, 108798. doi: https://doi.org/10.1016/j.steroids.2021.108798
  24. Banti C, Raptopoulou C, Psycharis V, Hadjikakou S. Novel silver glycinate conjugate with 3D polymeric intermolecular self-assembly architecture; an antiproliferative agent which induces apoptosis on human breast cancer cells. Journal of Inorganic Biochemistry. 2021, 216, 111351. doi: https://doi.org/10.1016/j.jinorgbio.2020.111351
  25. Banti C and Hadjikakou S. Evaluation of Toxicity with Brine Shrimp Assay. Bio-protocol 2021, 11(02): e3895. doi: https://doi.org/10.21769/BioProtoc.3895
  26. Mohr T, Katz S, Paulitschke V, Aizarani N, Tolios A. Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma. Cancers. 2021, 13, 1768. https://doi.org/10.3390/cancers13081768
  27. Kivrak A, Ulaş B, Kivrak H. A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2. International Immunopharmacology. 2021, 90, doi: 10.1016/j.intimp.2020.107232
  28. Ferreira RJ, Gajdács M, Kincses A, Spengler G, Dos Santos DJ, Ferreira MJU. Nitrogen-containing naringenin derivatives for reversing multidrug resistance in cancer. Bioorganic & Medicinal Chemistry. 2020, 28(23), 115798. doi: 10.1016/j.bmc.2020.115798
  29. Vasconcelos M H, Alcaro S, Arechavala-Gomeza V, Baumbach J, Borges F, Brevini T A L , De Las Rivas J, Devaux Y, Hozak P, Keinänen-Toivola M M, Giovanna Lattanzi G, Mohr T, Murovska M, Prusty B K, Quinlan R A, Pérez-Sala D, Scheibenbogen C, Schmidt H H W, Silveira I, Tieri P, Tolios A, Riganti C. Joining European Scientific Forces to Face Pandemics. Trends in Microbiology. 2020, doi: 10.1016/j.tim.2020.10.008
  30. Hurtová M, Biedermann D, Kuzma M, Křen V. Mild and Selective Method of Bromination of Flavonoids. Journal of Natural Products. 2020, 83 (11), 3324. doi: 10.1021/acs.jnatprod.0c00655
  31. Viktorová J, Kumar R, Řehořová K, Hoang L, Ruml T, Figueroa CR, Valdenegro M, Fuentes L. Antimicrobial Activity of Extracts of Two Native Fruits of Chile: Arrayan (Luma apiculata) and Peumo (Cryptocarya alba). Antibiotics. 2020, 9(8), 444. doi: 10.3390/antibiotics9080444
  32. Viktorová J, Stupák M, Řehořová K, Dobiasová S, Hoang L, Hajšlová J, Thanh TV, Tri LV, Tuan NV, Ruml T. Lemon Grass Essential Oil Does not Modulate Cancer Cells Multidrug Resistance by Citral—Its Dominant and Strongly Antimicrobial Compound. Foods. 2020, 9(5), 585. doi: 10.3390/foods9050585
  33. Tran VN, Viktorova J, Augustynkova K, Jelenova N, Dobiasova S, Rehorova K, Fenclova M, Stranska-Zachariasova M, Vitek L, Hajslova J, Ruml T. In Silico and In Vitro Studies of Mycotoxins and Their Cocktails; Their Toxicity and Its Mitigation by Silibinin Pre-Treatment. Toxins. 2020, 12(3), 148. doi: 10.3390/toxins12030148
  34. Dobiasová S, Řehořová K, Kučerová D, Biedermann D, Káňová K, Petrásková L, Koucká K, Václavíková R, Valentová K, Ruml T, Macek T. Multidrug Resistance Modulation Activity of Silybin Derivatives and Their Anti-Inflammatory Potential. Antioxidants. 2020, 9(5), 455. doi: 10.3390/antiox9050455
  35. Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resistance Updates 2020, 53, 100715. doi: 10.1016/j.drup.2020.100715
  36. Durante M, Frosini M, Fusi F, Gamberucci A, Chegaev K, Rolando B, Riganti C, Fruttero R, Saponara S. In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. European Journal of Pharmacology 2020, 880, 173164. doi: 10.1016/j.ejphar.2020.173164
  37. Palmeira A, Sousa E, Köseler A, Sabirli R, Gören T, Türkçüer İ, Kurt Ö, Pinto M, Vasconcelos MH. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13(6), 132; doi: 10.3390/ph13060132
  38. Dinić J, Efferth T, Garcia-Sosa A, Grahovac J, Padrón J, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. Drug Resistance Updates 2020, , 100713. doi: 10.1016/j.drup.2020.100713
  39. Lepeltier E, Rijo P, Rizzolio F, Popovtzer R, Petrikaite V, Assaraf YG, Passirani C. Nanomedicine to Target Multidrug Resistant Tumors. Drug Resistance Updates 2020, 52, 100704. doi: 10.1016/j.drup.2020.100704
  40. Isca V, Sencanski M, Filipovic N, Dos Santos D, Čipak Gašparović A, Saraíva L, Afonso C, Rijo P, García-Sosa A. Activity to Breast Cancer Cell Lines of Different Malignancy and Predicted Interaction with Protein Kinase C Isoforms of Royleanones. International Journal of Molecular Sciences 2020, 21, 3671. doi: 10.3390/ijms21103671
  41. Isca V, Ferreira R, Garcia C, Monteiro C, Dinic J, Holmstedt S, André V, Pešić M, Dos Santos D, Candeias N, Afonso C, Rijo P. Molecular Docking Studies of Royleanone Diterpenoids from Plectranthus spp. as P-Glycoprotein Inhibitors. ACS Medicinal Chemistry Letters 2020, 11, 839-845. doi: 10.1021/acsmedchemlett.9b00642
  42. Stark M, Silva, TFD, Levin G, Machuqueiro M, Assaraf YG. The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane. Cells 2020, 9, 1082. doi: 10.3390/cells9051082
  43. Fathy Abd-Ellatef GE, Gazzano E, Chirio D, Hamed AR, Belisario DC, Zuddas C, Peira E, Rolando B, Kopecka J, Assem Said Marie M, Sapino S, Ramadan Fahmy S, Gallarate M, Abdel-Hamid AZ, Riganti C. Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. Pharmaceutics. 2020, 12, E96. doi: 10.3390/pharmaceutics12020096
  44. Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, Tsakovska I, Zidar N, Fruttero R. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resistance Updates 2020, 50, 100682. doi: 10.1016/j.drup.2020.100682
  45. Kopecka J, Trouillas P, Gašparović AČ, Gazzano E, Assaraf YG, Riganti C. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Drug Resistance Updates 2020, 49, 100670. doi: 10.1016/j.drup.2019.100670
  46. Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates 2020, 48, 100662. doi: 10.1016/j.drup.2019.100662
  47. Andrei L, Kasas S, Ochoa Garrido I, Stanković T, Korsnes MS, Vaclavikovak R, Assaraf YG, Pešić M. Advanced technological tools to study multidrug resistance in cancer. Drug Resistance Updates 2020, 48, 100658. doi: 10.1016/j.drup.2019.100658
  48. Dömötör O, Kiss MA, Gál GT, May NV, Spengler G, Nové M, Gašparović AČ, Frank É, Enyedy ÉA. Solution equilibrium, structural and cytotoxicity studies on Ru(η(6)-p-cymene) and copper complexes of pyrazolyl thiosemicarbazones. Journal of Inorganic Biochemistry 2020, 202, 110883. doi: 10.1016/j.jinorgbio.2019.110883.
  49. Dinić J, Ríos-Luci C, Karpaviciene I, Cikotiene I, Fernandes MX, Pešić M, Padrón JM. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells. Investigational New Drugs 2020, 38, 584-598. doi: 10.1007/s10637-019-00803-6
  50. Szemeredi N, Kincses A, Rehorova K, Hoang L, Salardon-Jimenez N, Sevilla-Hernandez C, et al. Ketone- and Cyano-Selenoesters to Overcome Efflux Pump, Quorum-Sensing, and Biofilm-Mediated Resistance. Antibiotics. 2020, 9(12), 896. doi: 10.3390/antibiotics9120896
  51. Vasconcelos MH, Caires HR, Ābols A, Xavier CPR, Linē A. Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. Drug Resistance Updates 2019, 47, 100647. doi: 10.1016/j.drup.2019.100647
  52. Sarmento-Ribeiro AB, Scorilas A, Gonçalves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates 2019, 47, 100646. doi: 10.1016/j.drup.2019.100646
  53. Lazzarato L, Gazzano E, Blangetti M, Fraix A, Sodano F, Picone GM, Fruttero R, Gasco A, Riganti C, Sortino S. Combination of PDT and NOPDT with a Tailored BODIPY Derivative. Antioxidants 2019, 8, E531. doi: 10.3390/antiox8110531
  54. Puerta A, Galán AR, Abdilla R, Demanuele K, Fernandes MX, Bosica G, Padrón JM. Naphthol-derived Betti bases as potential SLC6A14 blockers. Journal of Molecular and Clinical Medicine 2019, 2, 35-40. doi: 10.31083/j.jmcm.2019.02.7181
  55. Gazzano E, Kopecka J, Belisario CD, Costamagna C, Riganti C.  A new LDL-masked liposomal doxorubicin overcomes drug resistance in osteosarcoma. Journal of Molecular and Clinical Medicine 2019, 2, 1-9. doi: 10.31083/j.jmcm.2019.01.6161
  56. Garcia C, Ntungwe E, Rebelo A, Bessa C, Stankovic T, Dinic J, Díaz-Lanza A, Reis CP, Roberto A, Pereira P, Cebola M-J, Saraiva L, Pešić M, Duarte N, Rijo P. Parvifloron D from Plectranthus strigosus: Cytotoxicity screening of Plectranthus spp. extracts. Biomolecules 2019, 9, 616. doi: 10.3390/biom9100616
  57. Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPE, Vasconcelos H. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019, 46, 100645. doi: 10.1016/j.drup.2019.100645
  58. Alexa-Stratulat T, Pešić M, Gašparović AČ, Trougakos IP, Riganti C. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resistance Updates 2019, 46, 100643. doi: 10.1016/j.drup.2019.100643
  59. Dinić J, Podolski-Renić A, Jovanović M, Musso L, Tsakovska I, Pajeva I, Dallavalle S, Pešić M. Novel Heat Shock Protein 90 inhibitors suppress P-glycoprotein activity and overcome multidrug resistance in cancer cells. International Journal of Molecular Sciences 2019,  20, 4575. doi: 10.3390/ijms20184575.
  60. Viktorová J, Dobiasová S, Řehořová K, Biedermann D, Káňová  K, Šeborová K, Václavíková R, Valentová K, Ruml T, Křen V, Macek T. Antioxidant, anti-inflammatory, and multidrug resistance modulation activity of silychristin derivatives. Antioxidants 2019, 8, 303. doi: 10.3390/antiox8080303
  61. Podolski-Renić A, Dinić J, Stanković T, Jovanović M, Ramović A, Pustenko A, Žalubovskis R, Pešić M. Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance. European Journal of Pharmaceutical Sciences 2019, 138, 105012. doi: 10.1016/j.ejps.2019.105012
  62. Rodrigues C, Milković L, Tartaro Bujak I, Tomljanović M, Soveral G, Gašparović AČ. Lipid profile and aquaporin expression under oxidative stress in breast cancer cells of different malignancies. Oxidative Medicine and Cellular Longevity 2019, 2019, 2061830. doi: 10.1155/2019/2061830
  63. Gazzano E, Kopecka J, Castella B, Buondonno I, Costamagna C, Riganti C. Novel anthracyclines with enhanced immunogenic effects against drug resistant osteosarcoma cells. Journal of Molecular and Clinical Medicine 2018, 1, 227-236. doi: 10.31083/j.jmcm.2018.04.325001